NVS logo

Novartis AG (NVS) EBITDA

Annual EBITDA

$20.71 B
+$2.46 B+13.48%

December 31, 2024

Summary

Performance

1-Year Change

+13.48%

3-Year Change

-32.99%

5-Year Change

+32.65%

15-Year Change

+42%

NVS EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

99.84%
NVS annual EBITDA is higher than 99.84% of companies in Healthcare sector

High & Low

All-time High

$30.91 B
NVS annual EBITDA is currently -32.99% below its historical high of $30.91 billion

3-Year Low

$14.68 B
NVS annual EBITDA is currently +41.09% above its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2024
NVS previous annual earnings announcement was published on Dec 31, 2024

Next Annual Earnings Report Date

N/A
NVS next annual earnings announcement has not yet been scheduled

OtherNVSprofitabilitymetrics:

Annual Revenue

$51.72 B
NVS annual revenue is $51.72 billion

Annual Net Income

$11.94 B
NVS annual net profit is $11.94 billion

Annual EBIT

$14.65 B
NVS annual earnings before interest & taxes is $14.65 billion

Annual EPS

$5.87
NVS annual earnings per share is $5.87

Quarterly EBITDA

$5.19 B
-$426.00 M-7.59%

December 31, 2024

Summary

Performance

3-Month Change

-7.59%

1-Year Change

+24.06%

3-Year Change

+6.2%

5-Year Change

+6.2%

NVS Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

99.83%
NVS quarterly EBITDA is higher than 99.83% of companies in Healthcare sector

High & Low

All-time High

$16.53 B
NVS quarterly EBITDA is currently -68.61% below its historical high of $16.53 billion

3-Year Low

$3.60 B
NVS quarterly EBITDA is currently +44.19% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
NVS previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

Apr 23, 2025
NVS next earnings announcement is scheduled for Apr 23, 2025

OtherNVSprofitabilitymetrics:

Quarterly Revenue

$13.56 B
NVS quarterly revenue is $13.56 billion

Quarterly Net Income

$2.82 B
NVS quarterly net profit is $2.82 billion

Quarterly EBIT

$3.56 B
NVS quarterly earnings before interest & taxes is $3.56 billion

Quarterly EPS

$1.41
NVS quarterly earnings per share is $1.41

TTM EBITDA

$20.71 B
+$1.01 B+5.10%

December 31, 2024

Summary

Performance

3-Month Change

+5.1%

1-Year Change

+13.48%

3-Year Change

+17.23%

5-Year Change

+17.23%

NVS TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

99.66%
NVS TTM EBITDA is higher than 99.66% of companies in Healthcare sector

High & Low

All-time High

$30.91 B
NVS TTM EBITDA is currently -32.99% below its historical high of $30.91 billion

3-Year Low

$15.63 B
NVS TTM EBITDA is currently +32.56% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
NVS previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

Apr 23, 2025
NVS next earnings announcement is scheduled for Apr 23, 2025

OtherNVSprofitabilitymetrics:

TTM Revenue

$51.72 B
NVS TTM revenue is $51.72 billion

TTM Net Income

$11.94 B
NVS TTM net profit is $11.94 billion

TTM EBIT

$14.65 B
NVS TTM earnings before interest & taxes is $14.65 billion

TTM EPS

$5.88
NVS TTM earnings per share is $5.88

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

Annual EBITDA

$20.71 B
NVS annual EBITDA is $20.71 billion

Annual Net Income

$11.94 B
NVS annual net profit is $11.94 billion

Annual Interest Expense

$1.01 B
NVS annual interest expense is $1.01 billion

Annual Income Tax

$1.70 B
NVS annual income tax is $1.70 billion

Annual D&A

$6.07 B
NVS annual depreciation & amortization is $6.07 billion

NVS EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+13.5%+24.1%+13.5%
3 y3 years-33.0%+6.2%+17.2%
5 y5 years+32.6%+6.2%+17.2%

NVS EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-33.0%+41.1%-68.6%+44.2%-33.0%+32.6%
5 y5-year-33.0%+41.1%-68.6%+44.2%-33.0%+32.6%
alltimeall time-33.0%+272.7%-68.6%+147.2%-33.0%+1480.1%

Novartis AG EBITDA History

DateAnnualQuarterlyTTM
Dec 2024
$20.71 B(+13.5%)
$5.19 B(-7.6%)
$20.71 B(+5.1%)
Sep 2024
-
$5.61 B(+7.0%)
$19.71 B(+3.8%)
Jun 2024
-
$5.25 B(+12.5%)
$18.98 B(+3.6%)
Mar 2024
-
$4.66 B(+11.5%)
$18.33 B(+0.4%)
Dec 2023
$18.25 B(+24.3%)
$4.18 B(-14.4%)
$18.25 B(+3.3%)
Sep 2023
-
$4.88 B(+6.2%)
$17.67 B(+7.1%)
Jun 2023
-
$4.60 B(+0.2%)
$16.49 B(+3.5%)
Mar 2023
-
$4.59 B(+27.6%)
$15.94 B(+2.0%)
Dec 2022
$14.68 B(-52.5%)
$3.60 B(-3.0%)
$15.63 B(-45.3%)
Sep 2022
-
$3.71 B(-8.4%)
$28.56 B(-4.0%)
Jun 2022
-
$4.05 B(-5.4%)
$29.73 B(-3.6%)
Mar 2022
-
$4.28 B(-74.1%)
$30.84 B(-0.2%)
Dec 2021
$30.91 B(+79.6%)
$16.53 B(+238.4%)
$30.91 B(+64.8%)
Sep 2021
-
$4.88 B(-5.2%)
$18.76 B(+2.9%)
Jun 2021
-
$5.15 B(+18.4%)
$18.23 B(+5.4%)
Mar 2021
-
$4.35 B(-0.6%)
$17.29 B(+0.5%)
Dec 2020
$17.21 B(+10.2%)
$4.38 B(+0.6%)
$17.21 B(+2.9%)
Sep 2020
-
$4.35 B(+3.4%)
$16.73 B(+2.0%)
Jun 2020
-
$4.21 B(-1.4%)
$16.41 B(+2.0%)
Mar 2020
-
$4.27 B(+9.5%)
$16.08 B(+3.0%)
Dec 2019
$15.62 B(-22.8%)
$3.90 B(-3.1%)
$15.62 B(+4.6%)
Sep 2019
-
$4.03 B(+3.6%)
$14.93 B(+1.2%)
Jun 2019
-
$3.88 B(+2.0%)
$14.75 B(-28.0%)
Mar 2019
-
$3.81 B(+18.3%)
$20.48 B(+1.2%)
Dec 2018
$20.24 B(+38.7%)
$3.22 B(-16.3%)
$20.24 B(+2.2%)
Sep 2018
-
$3.85 B(-60.0%)
$19.81 B(-1.3%)
Jun 2018
-
$9.61 B(+169.8%)
$20.07 B(+54.8%)
Mar 2018
-
$3.56 B(+27.8%)
$12.97 B(+12.5%)
Dec 2017
$14.59 B(+0.1%)
$2.79 B(-32.2%)
$11.53 B(-1.4%)
Sep 2017
-
$4.11 B(+64.0%)
$11.69 B(+1.3%)
Jun 2017
-
$2.51 B(+17.9%)
$11.54 B(-9.8%)
Mar 2017
-
$2.13 B(-27.8%)
$12.79 B(-12.2%)
Dec 2016
$14.57 B(+2.2%)
$2.95 B(-25.5%)
$14.57 B(+2.3%)
Sep 2016
-
$3.96 B(+5.2%)
$14.23 B(+2.0%)
Jun 2016
-
$3.76 B(-3.8%)
$13.96 B(-0.5%)
Mar 2016
-
$3.91 B(+49.4%)
$14.03 B(-1.6%)
Dec 2015
$14.26 B(-19.2%)
$2.61 B(-28.9%)
$14.26 B(-9.8%)
Sep 2015
-
$3.68 B(-3.9%)
$15.81 B(-7.1%)
Jun 2015
-
$3.83 B(-7.5%)
$17.02 B(-3.7%)
Mar 2015
-
$4.14 B(-0.6%)
$17.67 B(+0.1%)
Dec 2014
$17.66 B(+11.1%)
$4.17 B(-14.6%)
$17.66 B(+3.3%)
Sep 2014
-
$4.88 B(+8.8%)
$17.09 B(+7.1%)
Jun 2014
-
$4.49 B(+8.9%)
$15.97 B(+1.0%)
Mar 2014
-
$4.12 B(+14.5%)
$15.80 B(-0.5%)
Dec 2013
$15.89 B(-3.1%)
$3.60 B(-4.1%)
$15.89 B(-0.8%)
Sep 2013
-
$3.75 B(-13.2%)
$16.02 B(-2.6%)
Jun 2013
-
$4.33 B(+2.8%)
$16.46 B(-1.1%)
Mar 2013
-
$4.21 B(+12.8%)
$16.64 B(+1.5%)
Dec 2012
$16.40 B
$3.73 B(-11.0%)
$16.40 B(+4.7%)
Sep 2012
-
$4.19 B(-7.1%)
$15.66 B(-2.1%)
Jun 2012
-
$4.51 B(+13.7%)
$16.00 B(-1.9%)
DateAnnualQuarterlyTTM
Mar 2012
-
$3.97 B(+32.7%)
$16.31 B(-4.6%)
Dec 2011
$17.09 B(+8.1%)
$2.99 B(-34.1%)
$17.09 B(-2.2%)
Sep 2011
-
$4.53 B(-5.9%)
$17.48 B(+1.8%)
Jun 2011
-
$4.82 B(+1.4%)
$17.16 B(+6.3%)
Mar 2011
-
$4.75 B(+40.9%)
$16.14 B(+2.1%)
Dec 2010
$15.81 B(+23.8%)
$3.37 B(-20.1%)
$15.81 B(-0.4%)
Sep 2010
-
$4.22 B(+11.1%)
$15.88 B(+6.3%)
Jun 2010
-
$3.80 B(-14.2%)
$14.94 B(+4.7%)
Mar 2010
-
$4.42 B(+28.7%)
$14.27 B(+11.7%)
Dec 2009
$12.77 B(+2.5%)
$3.44 B(+4.9%)
$12.77 B(+9.0%)
Sep 2009
-
$3.28 B(+4.8%)
$11.72 B(-0.8%)
Jun 2009
-
$3.13 B(+6.8%)
$11.82 B(-1.3%)
Mar 2009
-
$2.93 B(+22.8%)
$11.98 B(-1.6%)
Dec 2008
$12.46 B(+17.7%)
$2.39 B(-29.3%)
$12.17 B(+3.0%)
Sep 2008
-
$3.38 B(+2.7%)
$11.82 B(+3.3%)
Jun 2008
-
$3.29 B(+5.3%)
$11.44 B(+6.2%)
Mar 2008
-
$3.12 B(+53.4%)
$10.78 B(+2.3%)
Dec 2007
$10.58 B(+3.9%)
$2.04 B(-32.1%)
$10.53 B(-7.3%)
Sep 2007
-
$3.00 B(+14.1%)
$11.36 B(+4.2%)
Jun 2007
-
$2.63 B(-8.7%)
$10.91 B(+1.4%)
Mar 2007
-
$2.88 B(+0.3%)
$10.76 B(+3.8%)
Dec 2006
$10.18 B(+16.0%)
$2.87 B(+12.8%)
$10.37 B(+5.9%)
Sep 2006
-
$2.54 B(+2.8%)
$9.79 B(+1.6%)
Jun 2006
-
$2.47 B(-0.5%)
$9.63 B(+3.5%)
Mar 2006
-
$2.49 B(+8.7%)
$9.30 B(+5.9%)
Dec 2005
$8.78 B(+10.2%)
$2.29 B(-4.1%)
$8.78 B(+3.3%)
Sep 2005
-
$2.39 B(+11.3%)
$8.50 B(+4.2%)
Jun 2005
-
$2.14 B(+9.1%)
$8.16 B(+0.4%)
Mar 2005
-
$1.97 B(-2.2%)
$8.13 B(+2.0%)
Dec 2004
$7.97 B(+9.8%)
$2.01 B(-1.8%)
$7.97 B(-0.2%)
Sep 2004
-
$2.05 B(-3.0%)
$7.98 B(+2.8%)
Jun 2004
-
$2.11 B(+17.0%)
$7.77 B(+4.8%)
Mar 2004
-
$1.80 B(-10.9%)
$7.41 B(+2.0%)
Dec 2003
$7.26 B(+1.0%)
$2.02 B(+10.5%)
$7.26 B(-8.1%)
Sep 2003
-
$1.83 B(+4.5%)
$7.90 B(+4.6%)
Jun 2003
-
$1.75 B(+5.9%)
$7.56 B(+4.3%)
Mar 2003
-
$1.66 B(-37.9%)
$7.25 B(-30.6%)
Dec 2002
$7.19 B(+20.9%)
$2.67 B(+79.5%)
$10.45 B(-796.4%)
Sep 2002
-
$1.49 B(+3.1%)
-$1.50 B(-158.0%)
Jun 2002
-
$1.44 B(-70.3%)
$2.59 B(+22.2%)
Mar 2002
-
$4.86 B(-152.3%)
$2.12 B(+24.6%)
Dec 2001
$5.95 B(+5.7%)
-$9.29 B(-266.6%)
$1.70 B(>+9900.0%)
Sep 2001
-
$5.58 B(+474.3%)
$0.00(-100.0%)
Jun 2001
-
$971.00 M(-78.1%)
-$695.00 M(+4.4%)
Mar 2001
-
$4.44 B(-140.4%)
-$666.00 M(-212.7%)
Dec 2000
$5.63 B(+1.2%)
-$10.99 B(-325.1%)
$591.00 M(-94.9%)
Sep 2000
-
$4.88 B(+388.1%)
$11.58 B(+72.9%)
Jun 2000
-
$1.00 B(-82.4%)
$6.70 B(+17.6%)
Mar 2000
-
$5.70 B
$5.70 B
Dec 1999
$5.56 B(-7.9%)
-
-
Dec 1998
$6.04 B
-
-

FAQ

  • What is Novartis AG annual EBITDA?
  • What is the all time high annual EBITDA for Novartis AG?
  • What is Novartis AG annual EBITDA year-on-year change?
  • What is Novartis AG quarterly EBITDA?
  • What is the all time high quarterly EBITDA for Novartis AG?
  • What is Novartis AG quarterly EBITDA year-on-year change?
  • What is Novartis AG TTM EBITDA?
  • What is the all time high TTM EBITDA for Novartis AG?
  • What is Novartis AG TTM EBITDA year-on-year change?

What is Novartis AG annual EBITDA?

The current annual EBITDA of NVS is $20.71 B

What is the all time high annual EBITDA for Novartis AG?

Novartis AG all-time high annual EBITDA is $30.91 B

What is Novartis AG annual EBITDA year-on-year change?

Over the past year, NVS annual EBITDA has changed by +$2.46 B (+13.48%)

What is Novartis AG quarterly EBITDA?

The current quarterly EBITDA of NVS is $5.19 B

What is the all time high quarterly EBITDA for Novartis AG?

Novartis AG all-time high quarterly EBITDA is $16.53 B

What is Novartis AG quarterly EBITDA year-on-year change?

Over the past year, NVS quarterly EBITDA has changed by +$1.01 B (+24.06%)

What is Novartis AG TTM EBITDA?

The current TTM EBITDA of NVS is $20.71 B

What is the all time high TTM EBITDA for Novartis AG?

Novartis AG all-time high TTM EBITDA is $30.91 B

What is Novartis AG TTM EBITDA year-on-year change?

Over the past year, NVS TTM EBITDA has changed by +$2.46 B (+13.48%)